AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant
A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat
BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.
Nine months after filing their TROP2-directed antibody-drug conjugate Dato-DXd for a lung cancer indication with the FDA, Daiichi Sankyo and AstraZeneca have pulled the submission.